Vrihad��rańyakam, Kát́hakam, íc��a, Kena, Muńd��akam; oder, Funf [!] Upanishads aus dem Yaǵur-,

Mode of access: Internet.

M. Tullius Cicero inde ab Idibus Martiis 710 usque ad Calendas Januarias 711 p. R. c. [microform]...

Academic program.

History of Switzerland, from B.C. 110, to A.D. 1830.

Includes index.

A vindication of the literary classes in the University of Edinburgh, against the aspersions of Peter Morris, M.D. Addressed to the Rev. Dr. J.S.

Mode of access: Internet.

Stories from English history from B. C. 55 to A. D. 1901;

Mode of access: Internet.

Maintenance, direct support, and general support level : transmission, model 3053A, NSN 2520-00-884-4833 : transmission transfers, model T-136-21, NSN 2520-00-001-7855, model T-136-27, NSN 2520-00-089-8287 : power takeoffs, model WN-7-28, NSN 2520-00-706-1137, model WND-7-28, NSN 2520-00-706-1136, model P-136-C, NSN 2520-00-229-5673.

Includes index.

Organizational/field/intermediate/DS, GS, and depot maintenance with illustrated parts breakdown : control, transponder set, C-6280(P)/APX, C-6280A(P)/APX, C-6717/APX, & C-7483/APX : Admiral aircraft radio.

"1 November 1969."

Sanctus in C major; Sanctus in D major; Sanctus in D minor; Sanctus in G major; Sanctus in D major; Kyrie eleison; Christe eleison; Sinfonia in F major /

Mode of access: Internet.

The Formation and Circulation of Early Yanzi Lore, Fourth Century B.C. - Third Century A.D.

Thesis (Ph.D.)--University of Washington, 2016-06

Régulation du récepteur natriurétique de type C par le monoxyde d'axote dans les cellules musculaires lisses vasculaires

Mémoire numérisé par la Direction des biblioth��ques de l'Université de Montréal.

Régulation du récepteur natriurétique de type C par le monoxyde d'axote dans les cellules musculaires lisses vasculaires

Mémoire numérisé par la Direction des biblioth��ques de l'Université de Montréal.

Evaluación del efecto broncodilatador de B2 Adrenérgico y anticolenérgico en E.P.O.C. tipo bronquitis crónica

Se trata de un estudio clínico comparativo en el que se busca evaluar la respuesta broncodilatadora del Bromuro de Ipratropia y del Bromhidrato de Fenoterol en pacientes con EPOC [Enfermedad pulmonar obstructiva]. tipo bronquitis crónica. El universo estuvo conformado por pacientes con su diagnóstico clínico que acudieron a consulta externa del Hospital Vicente Corral Moscoso de la ciudad de Cuenca. Se realizó la historia clínica y luego se procedió a realizar la espirografía de base y a los cinco y sesenta minutos después de ser administrados los fármacos en forma inhalatoria mediante sistema aleatorio. Para determinar el grado de respuesta broncodilatadora y comprobar la efectividad de los fármacos nos basamos en la expirometría basal que se confrontó con los valores de la segunda y tercera prueba, los parámetros estudiados fueron: Capacidad vital forzada [CVF], volumen espiratorio forzado en el primer segundo [VEF 1seg], Indice de Tiffeneau [VEF 1 seg/CVF] y los efectos colaterales presentados con la administración de los fármacos, que se identificaron mediante signos y síntomas de pacientes. En la investigación se determinó que al comparar a todos los pacientes con EPOC, que recibieron Bromuro de Ipratropio y Bromhidrato de Fenoterol, no se encuentran diferencias significativas [p mayor 0.05], la diferencia más grande encontrada es al comparar el VEF 1 seg. entre los dos grupos de estudio. En el tratamiento de la EPOC tipo bronquitis crónica los dos fármacos estudiados pueden ser utilizados indistintamente como broncodilatadores, sin embargo el Bromuro de Ipratropio tiene menos efectos secundarios

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide : Phase I clinical trial of three dosing schedules in patients with solid malignancies

Thalidomide is an anti-angiogenic agent currently used to treat patients with malignant cachexia or multiple myeloma. Lenalidomide (CC-5013) is an immunomodulatory thalidomide analogue licensed in the United States of America (USA) for the treatment of a subtype of myelodysplastic syndrome. This two-centre, open-label phase I study evaluated dose-limiting toxicities in 55 patients with malignant solid tumours refractory to standard chemotherapies. Lenalidomide capsules were consumed once daily for 12 weeks according to one of the following three schedules: (I) 25 mg daily for the first 7 d, the daily dose increased by 25 mg each week up to a maximum daily dose of 150 mg; (II) 25 mg daily for 21 d followed by a 7-d rest period, the 4-week cycle repeated for 3 cycles; (III) 10 mg daily continuously. Twenty-six patients completed the study period. Two patients experienced a grade 3 hypersensitivity rash. Four patients in cohort I and 4 patients in cohort II suffered grade 3 or 4 neutropaenia. In 2 patients with predisposing medical factors, grade 3 cardiac dysrhythmia was recorded. Grade 1 neurotoxicity was detected in 6 patients. One complete and two partial radiological responses were measured by computed tomography scanning; 8 patients had stable disease after 12 weeks of treatment. Fifteen patients remained on treatment as named patients; 1 with metastatic melanoma remains in clinical remission 3.5 years from trial entry. This study indicates the tolerability and potential clinical efficacy of lenalidomide in patients with advanced solid tumours who have previously received multi-modality treatment. Depending on the extent of myelosuppressive pre-treatment, dose schedules (II) or (III) are advocated for large-scale trials of long-term administration. © 2006 Elsevier Ltd. All rights reserved.